証券コード: 603520
Jiangxi Starry annual production of 1,500 tons of triiodoisophthaloyl chloride change project (Phase 1 project) completed
2018-10-25
About Jiangxi Starry Pharmaceutical Co., Ltd.'s annual output of 1,500 tons of triiodoisophthaloyl chloride change project (Phase 1 project) completed
Pursuant to the requirements of laws and regulations of the Environmental Protection Law of the People's Republic of China and the “Environmental Management Regulations for Construction Projects” and other regulations, in order to extensively solicit and understand the public's change of Jiangxi Starry Pharmaceutical Co., Ltd.'s annual output of 1,500 tons of triiodoisophthaloyl chloride (Phase I) Opinions on the environmental protection acceptance of the completion of the project, the environmental protection acceptance information of the completion of the project is now published as follows:
First, the basic situation of the project
Project Name: Jiangxi Starry Pharmaceutical Co., Ltd. Annual Change Project of 1,500 Tons of Triiodoisophthaloyl Chloride (Phase I Project)
Construction unit: Jiangxi Starry Pharmaceutical Co., Ltd.
Construction site: North side of Wuyi Road, Salt Chemical Industry Base, Zhangshu City, Jiangxi Province
EIA compilation unit: Guangzhou Environmental Protection Engineering Design Institute Co., Ltd.
Acceptance report preparation unit: Jiangxi Hongji Engineering Consulting Co., Ltd.
Acceptance monitoring unit: Jiangxi Mengbaomei Environmental Testing Technology Co., Ltd.
Name and contact information of the construction unit
1. Name of construction unit: Jiangxi Starry Pharmaceutical Co., Ltd.
2. Address: North of Wuyi Road, Salt Chemical Industry Base, Zhangshu City, Jiangxi Province
3. Contact: Chen Weifei
4. Phone: 13858601166
Third, the main work of acceptance monitoring
(1) Exhaust gas emission monitoring; (2) Wastewater emission monitoring; (3) Noise emission monitoring; (4) Inspection of solid waste generation and disposal.
Fourth, the acceptance conclusion
Jiangxi Starry Pharmaceutical Co., Ltd. has completed 1500 tons of triiodoisophthaloyl chloride annual change project (Phase 1 project), complete the procedures, and better implemented the requirements of the environmental protection "three simultaneous" system. Letter, the acceptance data is basically complete, environmental protection measures have been basically completed in accordance with the requirements of the environmental impact assessment and approval, and the major pollutant indicators have reached the requirements of corresponding pollutant emission standards, meet the requirements of total volume control, meet the requirements of environmental protection facilities, and accept The group agreed that the project (Phase 1 project) passed the environmental protection acceptance of the completion.
V. Main Matters for Soliciting Public Opinion
In order to listen to the opinions and suggestions of all sectors of the society on the environmental protection work of the project, the inspection and monitoring of the project and the acceptance opinions are publicized (see the inspection report for the inspection in Annex 1 and the inspection opinions in Annex 2).
Publicity time: October 25th to November 23rd, 2018.
During the publicity period, if you have any objections to the above publicity content, please provide written feedback. Individuals must sign their real names and the company must affix their official seal.
関連ニュース
お問い合わせ
電話番号: 0576-87718628/021-37916067
浙江司太立製薬股份有限公司
住所: 浙江省台州市仙居県現代工業集聚区司太立大道1号
上海司太立製薬有限公司
住所: 上海市金山工業区茂業路500号
浙江台州海神製薬有限公司
住所: 浙江省化学原薬基地臨海園区
江西司太立製薬有限公司
住所: 江西省宜春市樟樹市樟樹市工業園区
Imax Diagnostic Imaging Limited
住所: Phoenix House, Room 137 Monahan Road, CorkT12H1XY Republic of lreland
メール: info@imaxdiagnostic.com
電話番号: 00353 21 451 9990
メッセージをお願いします